In their study, Yang et al found that 13.6% of AML patients unselected by family history have pathogenic or likely pathogenic variants of known cancer-predisposition genes.
In this issue of Blood, Yang et al(1) report on the germline screening of 391 patients from the BEAT acute myeloid leukemia (AML) study, finding that 13.6% of patients unselected by family history have pathogenic or likely pathogenic variants of known cancer-predisposition genes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据